

Simon J Harrison

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9362503/publications.pdf>

Version: 2024-02-01

167
papers

5,937
citations

81900

39
h-index

85541

71
g-index

167
all docs

167
docs citations

167
times ranked

7910
citing authors

#	ARTICLE	IF	CITATIONS
1	Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. <i>Leukemia</i> , 2010, 24, 22-32.	7.2	505
2	Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. <i>Lancet, The</i> , 2019, 394, 2096-2107.	13.7	435
3	Clinical Studies of Histone Deacetylase Inhibitors. <i>Clinical Cancer Research</i> , 2009, 15, 3958-3969.	7.0	334
4	Panobinostat in Patients With Relapsed/Refractory Hodgkin's Lymphoma After Autologous Stem-Cell Transplantation: Results of a Phase II Study. <i>Journal of Clinical Oncology</i> , 2012, 30, 2197-2203.	1.6	251
5	Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial. <i>Lancet Oncology, The</i> , 2020, 21, 1630-1642.	10.7	237
6	T-cell acute leukaemia exhibits dynamic interactions with bone marrow microenvironments. <i>Nature</i> , 2016, 538, 518-522.	27.8	159
7	The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy. <i>Blood</i> , 2011, 117, 1605-1613.	1.4	152
8	Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. <i>Lancet Oncology, The</i> , 2021, 22, e105-e118.	10.7	136
9	First-in-Human RNA Polymerase I Transcription Inhibitor CX-5461 in Patients with Advanced Hematologic Cancers: Results of a Phase I Dose-Escalation Study. <i>Cancer Discovery</i> , 2019, 9, 1036-1049.	9.4	129
10	Deciphering the molecular and biologic processes that mediate histone deacetylase inhibitor-induced thrombocytopenia. <i>Blood</i> , 2011, 117, 3658-3668.	1.4	128
11	A multicentre retrospective comparison of central nervous system prophylaxis strategies among patients with high-risk diffuse large B-cell lymphoma. <i>British Journal of Cancer</i> , 2014, 111, 1072-1079.	6.4	113
12	Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1. <i>Haematologica</i> , 2012, 97, 64-72.	3.5	109
13	Oseltamivir Resistance in Adult Oncology and Hematology Patients Infected with Pandemic (H1N1) 2009 Virus, Australia. <i>Emerging Infectious Diseases</i> , 2010, 16, 1068-1075.	4.3	108
14	The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma. <i>Blood</i> , 2014, 124, 2190-2195.	1.4	108
15	Gene-modified T cells as immunotherapy for multiple myeloma and acute myeloid leukemia expressing the Lewis Y antigen. <i>Gene Therapy</i> , 2010, 17, 678-686.	4.5	105
16	CRISPR/Cas9 mediated deletion of the adenosine A2A receptor enhances CAR T cell efficacy. <i>Nature Communications</i> , 2021, 12, 3236.	12.8	99
17	Risks, severity and timing of infections in patients with multiple myeloma: a longitudinal cohort study in the era of immunomodulatory drug therapy. <i>British Journal of Haematology</i> , 2015, 171, 100-108.	2.5	94
18	A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma. <i>Blood</i> , 2011, 118, 6274-6283.	1.4	83

#	ARTICLE	IF	CITATIONS
19	A Phase 1 First in Human (FIH) Study of AMG 701, an Anti-B-Cell Maturation Antigen (BCMA) Half-Life Extended (HLE) BiTE [®] (bispecific T-cell engager) Molecule, in Relapsed/Refractory (RR) Multiple Myeloma (MM). <i>Blood</i> , 2020, 136, 28-29.	1.4	83
20	Update and new approaches in the treatment of Castleman disease. <i>Journal of Blood Medicine</i> , 2016, Volume 7, 145-158.	1.7	79
21	Enumeration, functional responses and cytotoxic capacity of MAIT cells in newly diagnosed and relapsed multiple myeloma. <i>Scientific Reports</i> , 2018, 8, 4159.	3.3	79
22	Inhibition of Pol I transcription treats murine and human AML by targeting the leukemia-initiating cell population. <i>Blood</i> , 2017, 129, 2882-2895.	1.4	74
23	Limited role for surveillance PET-CT scanning in patients with diffuse large B-cell lymphoma in complete metabolic remission following primary therapy. <i>British Journal of Cancer</i> , 2013, 109, 312-317.	6.4	64
24	Invasive fungal infections in patients with multiple myeloma: a multi-center study in the era of novel myeloma therapies. <i>Haematologica</i> , 2015, 100, e28-e31.	3.5	62
25	A phase 1 clinical trial evaluating marizomib, pomalidomide and low-dose dexamethasone in relapsed and refractory multiple myeloma (NPI-0052-107): final study results. <i>British Journal of Haematology</i> , 2018, 180, 41-51.	2.5	62
26	Targeting histone acetylation dynamics and oncogenic transcription by catalytic P300/CBP inhibition. <i>Molecular Cell</i> , 2021, 81, 2183-2200.e13.	9.7	59
27	Initial Clinical Activity and Safety of BFCR4350A, a FcRH5/CD3 T-Cell-Engaging Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2020, 136, 42-43.	1.4	58
28	Phase I Clinical Trial of Marizomib (NPI-0052) in Patients with Advanced Malignancies Including Multiple Myeloma: Study NPI-0052-102 Final Results. <i>Clinical Cancer Research</i> , 2016, 22, 4559-4566.	7.0	56
29	Immune regulatory effects of panobinostat in patients with Hodgkin lymphoma through modulation of serum cytokine levels and T-cell PD1 expression. <i>Blood Cancer Journal</i> , 2014, 4, e236-e236.	6.2	54
30	Changing treatment paradigms for patients with plasma cell myeloma: Impact upon immune determinants of infection. <i>Blood Reviews</i> , 2014, 28, 75-86.	5.7	52
31	Infection risk with immunomodulatory and proteasome inhibitor-based therapies across treatment phases for multiple myeloma: A systematic review and meta-analysis. <i>European Journal of Cancer</i> , 2016, 67, 21-37.	2.8	49
32	Peripheral Blood CD34+ Cell Enumeration as a Predictor of Apheresis Yield: An Analysis of More Than 1,000 Collections. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 763-772.	2.0	48
33	Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Siltuximab in High-Risk Smoldering Multiple Myeloma. <i>Clinical Cancer Research</i> , 2019, 25, 3772-3775.	7.0	46
34	Marizomib irreversibly inhibits proteasome to overcome compensatory hyperactivation in multiple myeloma and solid tumour patients. <i>British Journal of Haematology</i> , 2016, 174, 711-720.	2.5	44
35	Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14). <i>Journal of Clinical Oncology</i> , 2021, 39, 3602-3612.	1.6	44
36	Perceived benefits and barriers to exercise for recently treated patients with multiple myeloma: a qualitative study. <i>BMC Cancer</i> , 2013, 13, 319.	2.6	43

#	ARTICLE	IF	CITATIONS
37	Distress and unmet needs during treatment and quality of life in early cancer survivorship: A longitudinal study of haematological cancer patients. <i>European Journal of Haematology</i> , 2017, 99, 423-430.	2.2	43
38	Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis. <i>Leukemia</i> , 2021, 35, 562-572.	7.2	43
39	A cohort study on the incidence and outcome of pulmonary embolism in trauma and orthopedic patients. <i>BMC Medicine</i> , 2014, 12, 39.	5.5	41
40	Ceritinib in patients with advanced anaplastic lymphoma kinase rearranged anaplastic large-cell lymphoma. <i>Blood</i> , 2015, 126, 1257-1258.	1.4	40
41	A focus on the preclinical development and clinical status of the histone deacetylase inhibitor, romidepsin (depsipeptide, Istodax®). <i>Epigenomics</i> , 2012, 4, 571-589.	2.1	39
42	Ex vivo culture of chimeric antigen receptor T cells generates functional CD8+ T cells with effector and central memory-like phenotype. <i>Gene Therapy</i> , 2010, 17, 1105-1116.	4.5	38
43	Natural killer T cell defects in multiple myeloma and the impact of lenalidomide therapy. <i>Clinical and Experimental Immunology</i> , 2013, 175, 49-58.	2.6	35
44	Myelosuppressive Therapies Significantly Increase Pro-Inflammatory Cytokines and Directly Cause Bone Loss. <i>Journal of Bone and Mineral Research</i> , 2015, 30, 886-897.	2.8	35
45	Global measures of peripheral blood-derived DNA methylation as a risk factor in the development of mature B-cell neoplasms. <i>Epigenomics</i> , 2016, 8, 55-66.	2.1	35
46	Emergence of central nervous system myeloma in the era of novel agents. <i>Hematological Oncology</i> , 2012, 30, 170-174.	1.7	34
47	Caregivers' information needs and their experiences of care during treatment are associated with elevated anxiety and depression: a cross-sectional study of the caregivers of renal cancer survivors. <i>Supportive Care in Cancer</i> , 2016, 24, 4177-4186.	2.2	34
48	The influence of unmet supportive care needs on anxiety and depression during cancer treatment and beyond: a longitudinal study of survivors of haematological cancers. <i>Supportive Care in Cancer</i> , 2017, 25, 3447-3456.	2.2	33
49	Considerations for pretransfusion immunohaematology testing in patients receiving the anti-CD38 monoclonal antibody daratumumab for the treatment of multiple myeloma. <i>Internal Medicine Journal</i> , 2018, 48, 210-220.	0.8	31
50	Risks and burden of viral respiratory tract infections in patients with multiple myeloma in the era of immunomodulatory drugs and bortezomib: experience at an Australian Cancer Hospital. <i>Supportive Care in Cancer</i> , 2015, 23, 1901-1906.	2.2	30
51	Prolonged survival with the early use of a novel extracorporeal photopheresis regimen in patients with Sars-CoV-2 syndrome. <i>Blood</i> , 2019, 134, 1346-1350.	1.4	29
52	Deep profiling of apoptotic pathways with mass cytometry identifies a synergistic drug combination for killing myeloma cells. <i>Cell Death and Differentiation</i> , 2020, 27, 2217-2233.	11.2	29
53	Multiple myeloma of the spine. <i>Neuroradiology Journal</i> , 2017, 30, 259-268.	1.2	28
54	Subgroup analysis of ICARIA-MM study in relapsed/refractory multiple myeloma patients with high-risk cytogenetics. <i>British Journal of Haematology</i> , 2021, 194, 120-131.	2.5	27

#	ARTICLE	IF	CITATIONS
55	Epidemiology of bloodstream infections in patients with myeloma receiving current era therapy. <i>European Journal of Haematology</i> , 2017, 98, 149-153.	2.2	26
56	The course of anxiety, depression and unmet needs in survivors of diffuse large B cell lymphoma and multiple myeloma in the early survivorship period. <i>Journal of Cancer Survivorship</i> , 2017, 11, 329-338.	2.9	25
57	Immunotherapy of multiple myeloma: the start of a long and tortuous journey. <i>Expert Review of Anticancer Therapy</i> , 2006, 6, 1769-1785.	2.4	22
58	M(yeloma)IXing up T maintenance. <i>Blood</i> , 2012, 119, 1-2.	1.4	22
59	Updated results from BELLINI, a phase III study of venetoclax or placebo in combination with bortezomib and dexamethasone in relapsed/refractory multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2020, 38, 8509-8509.	1.6	22
60	Pegfilgrastim compared with filgrastim for cytokine-alone mobilization of autologous haematopoietic stem and progenitor cells. <i>Bone Marrow Transplantation</i> , 2013, 48, 351-356.	2.4	21
61	Spontaneous onset and transplant models of the Vk*MYC mouse show immunological sequelae comparable to human multiple myeloma. <i>Journal of Translational Medicine</i> , 2016, 14, 259.	4.4	21
62	Upfront lower dose lenalidomide is less toxic and does not compromise efficacy for vulnerable patients with relapsed refractory multiple myeloma: final analysis of the phase II RevLite study. <i>British Journal of Haematology</i> , 2017, 177, 441-448.	2.5	21
63	High Response Rates with the Combination of Bortezomib, Dexamethasone and the Pan-Histone Deacetylase Inhibitor Romidepsin in Patients with Relapsed or Refractory Multiple Myeloma in a Phase I/II Clinical Trial. <i>Blood</i> , 2008, 112, 3698-3698.	1.4	20
64	Venetoclax Combined with Bortezomib and Dexamethasone for Patients with Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2016, 128, 975-975.	1.4	20
65	Management of systemic <sc>AL</sc> amyloidosis: recommendations of the Myeloma Foundation of Australia Medical and Scientific Advisory Group. <i>Internal Medicine Journal</i> , 2015, 45, 371-382.	0.8	19
66	Prevention of viral infections in patients with multiple myeloma: the role of antiviral prophylaxis and immunization. <i>Expert Review of Anti-Infective Therapy</i> , 2015, 13, 1325-1336.	4.4	19
67	Bisphosphonate guidelines for treatment and prevention of myeloma bone disease. <i>Internal Medicine Journal</i> , 2017, 47, 938-951.	0.8	19
68	Regulatory T Cells (Treg) Are Depressed in Patients with Relapsed/Refractory Multiple Myeloma (MM) and Increases towards Normal Range in Responding Patients Treated with Lenalidomide (LEN).. <i>Blood</i> , 2008, 112, 1696-1696.	1.4	19
69	Enhanced CML stem cell elimination in vitro by bryostatin priming with imatinib mesylate. <i>Experimental Hematology</i> , 2005, 33, 1140-1146.	0.4	18
70	Bortezomib added to high-dose melphalan as pre-transplant conditioning is safe in patients with heavily pre-treated multiple myeloma. <i>Bone Marrow Transplantation</i> , 2011, 46, 764-765.	2.4	18
71	Limited clinical benefit for surveillance PET-CT scanning in patients with histologically transformed lymphoma in complete metabolic remission following primary therapy. <i>Annals of Hematology</i> , 2014, 93, 1193-1200.	1.8	18
72	Physical Activity Preferences for People Living With Multiple Myeloma. <i>Cancer Nursing</i> , 2017, 40, E1-E8.	1.5	18

#	ARTICLE	IF	CITATIONS
73	Epidemiology and Risks of Infections in Patients With Multiple Myeloma Managed With New Generation Therapies. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 444-450.e3.	0.4	17
74	The utility and limitations of 18F-fluorodeoxyglucose positron emission tomography with computed tomography in patients with primary mediastinal B-cell lymphoma: single institution experience and literature review. <i>Leukemia and Lymphoma</i> , 2015, 56, 49-56.	1.3	16
75	Conventional Treatment for Multiple Myeloma Drives Premature Aging Phenotypes and Metabolic Dysfunction in T Cells. <i>Frontiers in Immunology</i> , 2020, 11, 2153.	4.8	16
76	Safety and Efficacy of Venetoclax (ABT-199/GDC-0199) in Combination with Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase 1b Results. <i>Blood</i> , 2015, 126, 3038-3038.	1.4	16
77	Bortezomib, cyclophosphamide, and dexamethasone: highly effective for rapid reversal of myeloma-associated hyperammonemic encephalopathy. <i>Leukemia and Lymphoma</i> , 2010, 51, 2299-2302.	1.3	15
78	Bispecific antibody therapy, its use and risks for infection: Bridging the knowledge gap. <i>Blood Reviews</i> , 2021, 49, 100810.	5.7	15
79	The potential of histone deacetylase inhibitors for the treatment of multiple myeloma. <i>Leukemia and Lymphoma</i> , 2008, 49, 385-387.	1.3	14
80	The evolving status of immunotherapies in multiple myeloma: the future role of bispecific antibodies. <i>British Journal of Haematology</i> , 2022, 196, 488-506.	2.5	14
81	Enumeration of blood dendritic cells in patients with multiple myeloma at presentation and through therapy. <i>Leukemia and Lymphoma</i> , 2008, 49, 2272-2283.	1.3	13
82	Bortezomib with high dose melphalan conditioning for autologous transplant is safe and effective in patients with heavily pretreated and high risk multiple myeloma. <i>Leukemia and Lymphoma</i> , 2013, 54, 1465-1472.	1.3	13
83	Treatment of patients with multiple myeloma who are eligible for stem cell transplantation: position statement of the Myeloma Foundation of Australia Medical and Scientific Advisory Group. <i>Internal Medicine Journal</i> , 2015, 45, 94-105.	0.8	13
84	Renal Impairment at Diagnosis in Myeloma: Patient Characteristics, Treatment, and Impact on Outcomes. Results From the Australia and New Zealand Myeloma and Related Diseases Registry. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e415-e424.	0.4	13
85	Systematic Review of Quality Improvement Interventions Directed at Cancer Specialists. <i>Journal of Clinical Oncology</i> , 2013, 31, 1583-1591.	1.6	12
86	A messenger at the door: cytomegalovirus retinitis in myeloma patients with progressive disease. <i>Transplant Infectious Disease</i> , 2013, 15, E134-8.	1.7	12
87	Early thymus and activation-regulated chemokine (TARC) reduction and response following panobinostat treatment in patients with relapsed/refractory Hodgkin lymphoma following autologous stem cell transplant. <i>Leukemia and Lymphoma</i> , 2014, 55, 1053-1060.	1.3	12
88	The Choice of Multiple Myeloma Induction Therapy Affects the Frequency and Severity of Oral Mucositis After Melphalan-Based Autologous Stem Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 291-296.	0.4	12
89	Minimal residual disease in multiple myeloma: defining the role of next generation sequencing and flow cytometry in routine diagnostic use. <i>Pathology</i> , 2021, 53, 385-399.	0.6	12
90	The Myeloma Landscape in Australia and New Zealand: The First 8 Years of the Myeloma and Related Diseases Registry (MRDR). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e510-e520.	0.4	12

#	ARTICLE	IF	CITATIONS
91	Plerixafor plus pegfilgrastim is a safe, effective mobilization regimen for poor or adequate mobilizers of hematopoietic stem and progenitor cells: a phase I clinical trial. <i>Bone Marrow Transplantation</i> , 2014, 49, 1056-1062.	2.4	11
92	Glucose-regulated protein 78 (GRP78) as a potential novel biomarker and therapeutic target in multiple myeloma. <i>Expert Review of Hematology</i> , 2020, 13, 1201-1210.	2.2	11
93	A Randomized Trial of Two 2-Dose Influenza Vaccination Strategies for Patients Following Autologous Hematopoietic Stem Cell Transplantation. <i>Clinical Infectious Diseases</i> , 2020, 73, e4269-e4277.	5.8	11
94	Updated analysis of a phase I/II study of venetoclax in combination with daratumumab and dexamethasone, +/- bortezomib, in patients with relapsed/refractory multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2020, 38, 8511-8511.	1.6	11
95	Treatment of patients with Waldenström macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory Group. <i>Internal Medicine Journal</i> , 2017, 47, 35-49.	0.8	10
96	Predicting Risk of Infection in Patients with Newly Diagnosed Multiple Myeloma: Utility of Immune Profiling. <i>Frontiers in Immunology</i> , 2017, 8, 1247.	4.8	10
97	CAR-T cell therapy: practical guide to routine laboratory monitoring. <i>Pathology</i> , 2021, 53, 408-415.	0.6	10
98	Lower-Dose Lenalidomide and Dexamethasone Reduces Toxicity without Compromising Efficacy In Patients with Relapsed/Refractory Myeloma, Who Are Aged ≥60 Years or Have Renal Impairment: Planned Interim Results of a Prospective Multicentre Phase II Trial. <i>Blood</i> , 2010, 116, 1961-1961.	1.4	10
99	Novel AKT Inhibitor GSK2110183 Shows Favorable Safety, Pharmacokinetics, and Clinical Activity in Multiple Myeloma. Preliminary Results From a Phase I First-Time-In-Human Study. <i>Blood</i> , 2011, 118, 1856-1856.	1.4	10
100	Predicting durable remissions following thalidomide therapy for relapsed myeloma. <i>Leukemia and Lymphoma</i> , 2009, 50, 223-229.	1.3	9
101	Histone deacetylase inhibitors reduce glycoprotein VI expression and platelet responses to collagen related peptide. <i>Thrombosis Research</i> , 2013, 131, 514-520.	1.7	9
102	Myeloma and pregnancy: strange bedfellows?. <i>Leukemia and Lymphoma</i> , 2014, 55, 966-968.	1.3	9
103	Safety and Efficacy of the Combination of Bortezomib with the Deacetylase Inhibitor Romidepsin in Patients with Relapsed or Refractory Multiple Myeloma: Preliminary Results of a Phase I Trial.. <i>Blood</i> , 2007, 110, 1167-1167.	1.4	9
104	Low Dose Lenalidomide and Dexamethasone Induction Followed by Autologous Transplantation In Untreated Patients with Myeloma Is Associated with High Response Rates and Preservation of CD8, but Not CD4 or NK Cellular Immunity. <i>Blood</i> , 2011, 118, 1862-1862.	1.4	9
105	Plasmacytoma of the testis in a patient with relapsed and refractory multiple myeloma: Case report and review of the literature. <i>Urology Annals</i> , 2015, 7, 530.	0.6	9
106	Complete remission of localised gastric plasmacytomas following definitive radiotherapy. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2012, 56, 328-331.	1.8	8
107	Outcomes Following Extracorporeal Photopheresis for Chronic Lung Allograft Dysfunction Following Lung Transplantation: A Single-Center Experience. <i>Transplantation Proceedings</i> , 2021, 53, 296-302.	0.6	8
108	Myeloma natural killer cells are exhausted and have impaired regulation of activation. <i>Haematologica</i> , 2021, 106, 2522-2526.	3.5	8

#	ARTICLE	IF	CITATIONS
109	Predictors of early mortality in multiple myeloma: Results from the Australian and New Zealand Myeloma and Related Diseases Registry (<sc>MRDR</sc>). <i>British Journal of Haematology</i> , 2022, 198, 830-837.	2.5	8
110	Overview of Histone Deacetylase Inhibitors in Haematological Malignancies. <i>Pharmaceuticals</i> , 2010, 3, 2674-2688.	3.8	7
111	The addition of dexamethasone to bortezomib for patients with relapsed multiple myeloma improves outcome but ongoing maintenance therapy has minimal benefit. <i>American Journal of Hematology</i> , 2015, 90, E86-91.	4.1	7
112	Antiviral prophylaxis for varicella zoster virus infections in patients with myeloma in the era of novel therapies. <i>Leukemia and Lymphoma</i> , 2016, 57, 1719-1722.	1.3	7
113	FDG-PET/CT in managing infection in patients with hematological malignancy: clinician knowledge and experience in Australia. <i>Leukemia and Lymphoma</i> , 2019, 60, 2471-2476.	1.3	7
114	Real-world utilisation of ASCT in multiple myeloma (MM): a report from the Australian and New Zealand myeloma and related diseases registry (MRDR). <i>Bone Marrow Transplantation</i> , 2021, 56, 2533-2543.	2.4	7
115	Early Pharmacodynamic Changes in T-Cell Activation, Proliferation, and Cytokine Production Confirm the Mode of Action of BFCR4350A, a FcRH5/CD3 T-Cell-Engaging Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2020, 136, 14-15.	1.4	7
116	Access, knowledge and experience with fluorodeoxyglucose positron emission tomography/computed tomography in infection management: a survey of Australia and New Zealand infectious diseases physicians and microbiologists. <i>Internal Medicine Journal</i> , 2019, 49, 615-621.	0.8	6
117	A Wolf in Sheep's clothing: A case report series of oral manifestations of multiple myeloma. <i>Australian Dental Journal</i> , 2021, 66, 324-331.	1.5	6
118	Australia and New Zealand Transplant and Cellular Therapies <sc>COVID-19</sc> vaccination consensus position statement. <i>Internal Medicine Journal</i> , 2021, 51, 1321-1323.	0.8	6
119	Isatuximab for relapsed/refractory multiple myeloma: review of key subgroup analyses from the Phase III ICARIA-MM study. <i>Future Oncology</i> , 2021, 17, 4797-4812.	2.4	6
120	Levofloxacin prophylaxis in patients with myeloma. <i>Lancet Oncology</i> , The, 2020, 21, e67.	10.7	6
121	GO39775: A multicenter phase I trial evaluating the safety, pharmacokinetics, and activity of BFCR4350A, a FcRH5/CD3 T-cell dependent bispecific antibody, in patients with relapsed or refractory multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS8551-TPS8551.	1.6	6
122	Neuroimaging findings in immune effector cell associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy. <i>Leukemia and Lymphoma</i> , 2022, 63, 2364-2374.	1.3	6
123	Low Uptake of Upfront Autologous Transplantation for Myeloma in a Jurisdiction With Universal Health Care Coverage: A Population-Based Patterns of Care Study in Australia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 61-67.	0.4	5
124	The Use of Optimal Treatment for DLBCL Is Improving in All Age Groups and Is a Key Factor in Overall Survival, but Non-Clinical Factors Influence Treatment. <i>Cancers</i> , 2019, 11, 928.	3.7	5
125	Low rates of invasive fungal disease in patients with multiple myeloma managed with new generation therapies: Results from a multi-centre cohort study. <i>Mycoses</i> , 2021, 64, 30-34.	4.0	5
126	The Addition of Systemic High-Dose Methotrexate (HD-MTX) to Intrathecal Chemotherapy (IT) for Central Nervous System (CNS) Prophylaxis Substantially Reduces CNS Recurrence Rates in Patients with at-Risk Aggressive Lymphoma: A Historically Controlled Prospective Study. <i>Blood</i> , 2008, 112, 3596-3596.	1.4	5

#	ARTICLE	IF	CITATIONS
127	Response: dexamethasone dose alters expression of NK activating receptors in vivo. <i>Blood</i> , 2011, 118, 6466-6468.	1.4	4
128	Comment on "Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma". <i>Haematologica</i> , 2015, 100, e379-e379.	3.5	4
129	Outcome of the Stryker® Trident All-Poly™ Constraint Acetabular Insert: A District General Hospital Experience. <i>HIP International</i> , 2015, 25, 557-562.	1.7	4
130	Engraftment syndrome manifesting as acute brachial neuropathy following high-dose chemotherapy for management of plasma cell myeloma. <i>Leukemia and Lymphoma</i> , 2016, 57, 2942-2945.	1.3	4
131	Time from autologous to allogeneic hematopoietic stem cell transplantation impacts post-transplant outcomes in multiple myeloma. <i>Bone Marrow Transplantation</i> , 2020, 55, 1172-1174.	2.4	4
132	Invariant NKT cells dictate antitumor immunity elicited by a bispecific antibody cotargeting CD3 and BCMA. <i>Blood Advances</i> , 2022, 6, 5165-5170.	5.2	4
133	The development of novel immunotherapeutic approaches in multiple myeloma. <i>Leukemia and Lymphoma</i> , 2008, 49, 652-654.	1.3	3
134	A Risk-Adapted Protocol for Delayed Administration of Filgrastim After High-Dose Chemotherapy and Autologous Stem Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 42-47.	0.4	3
135	Myeloma of the central nervous system – an ongoing conundrum!. <i>Leukemia and Lymphoma</i> , 2016, 57, 1505-1506.	1.3	3
136	Autologous stem cell transplantation in elderly multiple myeloma patients aged ≥65 years: a two-centre Australian experience. <i>Internal Medicine Journal</i> , 2021, 51, 280-283.	0.8	3
137	Successful identification of predictive profiles for infection utilising systems-level immune analysis: a pilot study in patients with relapsed and refractory multiple myeloma. <i>Clinical and Translational Immunology</i> , 2021, 10, e1235.	3.8	3
138	Alcohol and tobacco use and risk of multiple myeloma: A case-control study. <i>EJHaem</i> , 2022, 3, 109-120.	1.0	3
139	Erythrophagocytosis. <i>British Journal of Haematology</i> , 2001, 113, 2-2.	2.5	2
140	Aggressive and extramedullary plasma cell myeloma evade bone marrow flow cytometric minimal residual disease detection. <i>British Journal of Haematology</i> , 2016, 173, 947-949.	2.5	2
141	Retinal ischemia due to extramedullary plasmacytomas of the orbit. <i>Journal of Clinical Neuroscience</i> , 2020, 72, 447-449.	1.5	2
142	Paving the way to precision medicine in multiple myeloma. <i>Expert Review of Hematology</i> , 2021, 14, 323-327.	2.2	2
143	Receiving four or fewer cycles of therapy predicts poor survival in newly diagnosed transplant-ineligible patients with myeloma who are treated with bortezomib-based induction. <i>European Journal of Haematology</i> , 2021, 107, 497-499.	2.2	2
144	Review of Myeloma Therapies and Their Potential for Oral and Maxillofacial Side Effects. <i>Cancers</i> , 2021, 13, 4479.	3.7	2

#	ARTICLE	IF	CITATIONS
145	Phase 1 Clinical Trial of the Novel Structure Proteasome Inhibitor NPI-0052.. Blood, 2009, 114, 2693-2693.	1.4	2
146	First in-human study of in vivo imaging of ex vivo labeled CAR T cells with dual PET-MR.. Journal of Clinical Oncology, 2020, 38, 3557-3557.	1.6	2
147	Trends in Outcomes in Australia and New Zealand in Autologous Stem Cell Transplantation in Older Patients with Multiple Myeloma: An Australasian Bone Marrow Transplant Recipient Registry Study. Blood, 2020, 136, 11-12.	1.4	2
148	The Impact of S-Li-M Criteria in Myeloma in a Real-Life Population: Patient & Disease Characteristics, Treatment and Outcomes from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR). Blood, 2020, 136, 30-31.	1.4	2
149	CAMMA 1: A multicenter phase Ib trial evaluating the safety, pharmacokinetics, and activity of cevostamab-containing regimens in patients with relapsed or refractory multiple myeloma.. Journal of Clinical Oncology, 2022, 40, TPS8069-TPS8069.	1.6	2
150	Lessons Learned From an Unusual Presentation of CD3 ⁺ , CD56 ⁺ T-Cell Large Granular Lymphocyte Leukemia. Journal of Clinical Oncology, 2010, 28, e498-e502.	1.6	1
151	Hepatitis B reverse seroconversion despite entecavir prophylaxis in a myeloma patient on multiple novel agents: a case report and review of the literature. Leukemia and Lymphoma, 2021, 62, 1271-1274.	1.3	1
152	In Vivo Antagonistic Effects of Dexamethasone On Lenalidomide-Induced NK Cell Activation.. Blood, 2009, 114, 1639-1639.	1.4	1
153	Evaluation of minimal residual disease in relapsed/refractory multiple myeloma patients treated with venetoclax or placebo in combination with bortezomib and dexamethasone: BELLINI study analyses.. Journal of Clinical Oncology, 2020, 38, 8547-8547.	1.6	1
154	A Phase 1b Dose Escalation Safety Analysis of Lenalidomide and Azacitidine Maintenance Therapy for Poor Risk AML,. Blood, 2011, 118, 3625-3625.	1.4	1
155	Intravital Microscopy Reveals Fundamental Differences in the Interaction of Stem Cells and T Acute Lymphoblastic Leukaemia with the Bone Marrow Microenvironment. Blood, 2016, 128, 5199-5199.	1.4	1
156	Rapid and Sustained Reduction of Immunosuppressive T-Cells and Focusing of the T-Cell Repertoire in t(11;14) Relapsed/Refractory Multiple Myeloma Patients Treated with Venetoclax in Combination with Daratumumab and Dexamethasone. Blood, 2021, 138, 1633-1633.	1.4	1
157	Integrative Analysis of the Genomic and Transcriptomic Landscape of Relapsed/Refractory Multiple Myeloma Patients Treated With Venetoclax in Combination With Bortezomib and Dexamethasone: Biomarker Analyses From the Phase 3 BELLINI Study. Blood, 2020, 136, 40-41.	1.4	1
158	The impact of G-CSF alone vs G-CSF and cyclophosphamide mobilisation on autograft immune cell content in multiple myeloma. Bone Marrow Transplantation, 2022, 57, 1001-1003.	2.4	1
159	To validate: Is it so simple?. Transfusion and Apheresis Science, 2011, 45, 209-211.	1.0	0
160	KRd: the new KiD in the French myeloma induction class. Blood, 2021, 138, 105-106.	1.4	0
161	Gene-Modified CD8+ T Cells Undergo Functional Polarization to Effector and Central Memory Cells in Response to Antigen Exposure.. Blood, 2008, 112, 1531-1531.	1.4	0
162	Overcoming Histone Deacetylase Inhibitor Induced Thrombocytopenia Using a Thrombopoietin Mimetic.. Blood, 2009, 114, 2416-2416.	1.4	0

#	ARTICLE	IF	CITATIONS
163	Marizomib Overcomes Compensatory Hyperactivation of Trypsin-like and Caspase-like Subunits to Provide Pan-Proteasome Subunit Inhibition in Patients with Multiple Myeloma and Solid Tumors. Blood, 2015, 126, 5375-5375.	1.4	0
164	A Multicentre Study Investigating the Pharmacokinetics and Pharmacodynamics of Busulphan When Combined with Melphalan As Conditioning in Adult Autologous Transplant Recipients. Blood, 2016, 128, 2190-2190.	1.4	0
165	Assessing the Immune Tumour Microenvironment (iTME) Using Multiplex Immunofluorescence Histochemistry (mIHC) Demonstrates Close Proximity of Cytotoxic T-Cells to Plasma Cells (PC) in Patients with Newly Diagnosed Multiple Myeloma (NDMM). Blood, 2021, 138, 4705-4705.	1.4	0
166	The development of a home-based therapeutic platform for multiple myeloma. Expert Review of Hematology, 2021, , 1-7.	2.2	0
167	Carfilzomib Thalidomide and Dexamethasone Is Safe and Effective in the Treatment of Relapsed/Refractory Multiple Myeloma: An Open Label Phase II Australasian Leukaemia and Lymphoma Group (ALLG) MM 018/ Asian Myeloma Network (AMN) 002 Study. Blood, 2020, 136, 39-40.	1.4	0